1. Home
  2. IRMD vs GERN Comparison

IRMD vs GERN Comparison

Compare IRMD & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iRadimed Corporation

IRMD

iRadimed Corporation

HOLD

Current Price

$88.67

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.51

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRMD
GERN
Founded
1992
1990
Country
United States
United States
Employees
N/A
229
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
IRMD
GERN
Price
$88.67
$1.51
Analyst Decision
Strong Buy
Hold
Analyst Count
1
3
Target Price
$116.00
$2.17
AVG Volume (30 Days)
78.2K
18.3M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
0.89%
N/A
EPS Growth
16.67
N/A
EPS
1.75
N/A
Revenue
$83,814,000.00
N/A
Revenue This Year
$12.38
$26.91
Revenue Next Year
$11.31
$43.75
P/E Ratio
$51.58
N/A
Revenue Growth
14.43
N/A
52 Week Low
$50.36
$1.04
52 Week High
$107.90
$2.01

Technical Indicators

Market Signals
Indicator
IRMD
GERN
Relative Strength Index (RSI) 33.95 42.68
Support Level $82.64 $1.41
Resistance Level $105.87 $1.72
Average True Range (ATR) 2.73 0.10
MACD -0.45 -0.02
Stochastic Oscillator 0.00 8.11

Price Performance

Historical Comparison
IRMD
GERN

About IRMD iRadimed Corporation

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: